The COVID-19 pandemic continues to bring challenges to all of us on personal and professional levels but the importance of clinical research has perhaps never been higher. Our priority at George Clinical continues to be the safety and wellbeing of our employees, patients, investigators, clients and partners as we continue to execute critical studies in a wide range of therapeutic areas.

Advancing our mission to improve the health of millions of people worldwide has been even more evident since the pandemic began and we have remained steadfastly committed to ensuring our clinical research projects retain continuity in the midst of unprecedented challenges.

Our teams around the globe have shown remarkable resiliency under pressure, including efforts to implement new COVID-19 studies. We appreciate the healthcare workers, local communities, businesses and governmental personnel around the world who are on the front line managing their local situation and helping distribute vaccinations.

The measures we implemented in Q1 of 2020 across all of our offices have made a tangible difference in our ability to operate without losing the key ingredients of our proven operation model. Project-specific mitigation plans implemented last year ensured risks from the pandemic were well-considered and remote management of our clinical trials was instituted if on-site visits were not possible.

We recognize that these remain unsettling times but rest assured our teams will continue their vigilance and professionalism as we serve you effectively.


With health and gratitude,

James Cheong
Chief Executive Officer, George Clinical